Thyroid cancer

Perspective Announces Presentation of Positive Early Clinical Data for VMT-α-NET at the 36th Annual Congress of the European Association of Nuclear Medicine

Retrieved on: 
Tuesday, September 12, 2023
Pheochromocytoma, DOTATATE, NETS, MBBS, EANM, TAT, Thyroid cancer, Quality of life, DNB, Nuclear medicine, Paraganglioma, PET-CT, Șaeș, Non-small-cell lung cancer, MDS, Hair, Targeted molecular therapy for neuroblastoma, CATX, Patient, Standard of care, Syndrome, Molina Healthcare, FMRI, European Association for the Study of the Liver, Therapy, NYSE, PRRT, Meningioma, Safety, Fatigue, Pharmaceutical industry

Responses observed in both peptide receptor radionuclide therapy-naïve and peptide receptor radionuclide therapy-refractory disease.

Key Points: 
  • Responses observed in both peptide receptor radionuclide therapy-naïve and peptide receptor radionuclide therapy-refractory disease.
  • The results were presented at the 36th Annual Congress of the European Association of Nuclear Medicine (EANM), held in Vienna, Austria, from September 9-13, 2023.
  • Improvements in patients’ symptoms and quality of life trended strongly positive with consecutive [212Pb]VMT-α-NET doses.
  • We will continue to monitor patients’ progress, and we look forward to providing a more extensive data readout in the upcoming quarters.”

Jason Colodne and Colbeck Capital Support the MD Anderson Cancer Center at the University of Texas in Connection With Its Anaplastic Thyroid Cancer Research

Retrieved on: 
Tuesday, August 22, 2023
Biotechnology, Banking, Professional Services, Health, General Health, Pharmaceutical, Oncology, Research, Science, Clinical Trials, Finance, Survival, University, University of Texas at Austin, Cancer, ATC, MD Anderson Cancer Center, Education, Anaplastic thyroid cancer, Patient, Thyroid cancer, Pharmaceutical industry

Jason Colodne and Colbeck Capital Management (“Colbeck”) today announced their continued support of the MD Anderson Cancer Center at The University of Texas, one of the world’s most respected centers devoted exclusively to cancer patient care, research, education, and prevention, in connection with the center’s research to combat Anaplastic Thyroid Cancer (“ATC”).

Key Points: 
  • Jason Colodne and Colbeck Capital Management (“Colbeck”) today announced their continued support of the MD Anderson Cancer Center at The University of Texas, one of the world’s most respected centers devoted exclusively to cancer patient care, research, education, and prevention, in connection with the center’s research to combat Anaplastic Thyroid Cancer (“ATC”).
  • ATC is the most advanced and aggressive form of thyroid cancer and one of the fastest growing cancers, most commonly found in people over the age of 60.
  • Although less than 2% of patients with thyroid cancer have ATC, it is known as one of the most lethal malignancies with a current 5-year survival rate of 7%, accounting for approximately 40% of all thyroid cancer–related mortalities.
  • MD Anderson Cancer Center’s mission is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research, and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees, and the public.

INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR THE SECOND QUARTER AND FIRST SIX MONTHS OF 2023

Retrieved on: 
Monday, August 14, 2023
Maintenance, Operation, IDAHO, OTCQB, Sale, Thyroid cancer, Nuclear medicine, Three (TV channel), INIS, Growth, R, Cobalt, Calibration, Cryptocurrency, Rare-earth element, Fine chemical

Revenue for the six months ended June 30, 2023, was $6,201,700 compared to $5,242,249 for the same period in 2022.

Key Points: 
  • Revenue for the six months ended June 30, 2023, was $6,201,700 compared to $5,242,249 for the same period in 2022.
  • Revenue for the three months ended June 30, 2023, was $3,112,165 compared to $2,434,808 for the same period in 2022, an overall increase of approximately 28%.
  • The decrease in net income was primarily attributable to a one-time $1.8 million gain on the sale of assets during the first quarter of 2022.
  • As of June 30, 2023, cash and cash equivalents increased to $3,274,125 compared to $2,375,817 as of December 31, 2022.

InnoCare Announces Approval of Clinical Trial of pan-TRK Inhibitor Zurletrectinib for the Treatment of Pediatric Patients in China

Retrieved on: 
Wednesday, July 26, 2023
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Clinical trial, Cancer, Lung cancer, Thyroid cancer, Trial of the century, Sarcoma, SSE, HKEX, Patient, Colorectal cancer, NTRK, Adolescence, Safety, Breast cancer, TRK, Pharmaceutical industry

This is following the clinical trial of zurletrectinib for adolescent patients (12 to 18 years old) after showing good safety and efficacy in adult patients.

Key Points: 
  • This is following the clinical trial of zurletrectinib for adolescent patients (12 to 18 years old) after showing good safety and efficacy in adult patients.
  • Dr. Jasmine, the Co-founder, Chairwoman and CEO of InnoCare, said, “NTRK gene fusion is more common among pediatric patients.
  • By now, our clinical study with zurletrectinib has covered NTRK fusion patients at all ages.
  • We will continue to accelerate the clinical trials of zurletrectinib, looking forward to providing better treatment options for patients early.”

NCCN Debuts Roadmap for Improving Thyroid Cancer Care in Low- and Middle-Income Countries on World Stage

Retrieved on: 
Wednesday, June 14, 2023
FEBS, World Congress of Universal Documentation, Thyroid, Framework, FACE, American Academy of Otolaryngology–Head and Neck Surgery, Survival, Cancer, Research, Journal of the National Comprehensive Cancer Network, Dana–Farber Cancer Institute, Harvard Medical School, NCCN, Investment, Regius Professor of Medicine and Therapeutics, Translation, Pain management, Palliative care, FACS, Dana, Thyroid cancer, Breast cancer, Risk management, Medical device, Core, MD

PLYMOUTH MEETING, Pa. and LONDON, June 14, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) is introducing a new global resource to improve thyroid cancer care in low- and middle-income countries at the upcoming World Congress on Thyroid Cancer, in London. During the event, NCCN Senior Vice President and Chief Medical Officer, Wui-Jin Koh, MD, will present on NCCN's ongoing global work to define and advance high-quality, high-value, patient-centered cancer care. As part of that work, the non-profit alliance of leading cancer centers recently published the new NCCN Framework for Resource Stratification of NCCN Guidelines (NCCN Framework™) for Thyroid Carcinoma, available free-of-charge at NCCN.org/global. The new resource will debut in front of more than 1,000 cancer care providers from across the globe on June 17, 2023.

Key Points: 
  • NCCN Framework for Resource Stratification of the NCCN Guidelines (NCCN Framework™) for Thyroid Carcinoma to be presented at upcoming World Congress on Thyroid Cancer in London, UK.
  • PLYMOUTH MEETING, Pa. and LONDON, June 14, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) is introducing a new global resource to improve thyroid cancer care in low- and middle-income countries at the upcoming World Congress on Thyroid Cancer, in London.
  • NCCN Framework™ exists for numerous cancer types—covering more than 80 percent of cancer diagnoses—plus supportive care topics such as pain management, palliative care, and breast cancer prevention and detection.
  • The NCCN Framework™ for Thyroid Carcinoma is the first new cancer type to be added to this library in recent years.

NCCN Debuts Roadmap for Improving Thyroid Cancer Care in Low- and Middle-Income Countries on World Stage

Retrieved on: 
Wednesday, June 14, 2023
FEBS, World Congress of Universal Documentation, Thyroid, Framework, FACE, American Academy of Otolaryngology–Head and Neck Surgery, Survival, Cancer, Research, Journal of the National Comprehensive Cancer Network, Dana–Farber Cancer Institute, Harvard Medical School, NCCN, Investment, Regius Professor of Medicine and Therapeutics, Translation, Pain management, Palliative care, FACS, Dana, Thyroid cancer, Breast cancer, Risk management, Medical device, Core, MD

PLYMOUTH MEETING, Pa. and LONDON, June 14, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) is introducing a new global resource to improve thyroid cancer care in low- and middle-income countries at the upcoming World Congress on Thyroid Cancer, in London. During the event, NCCN Senior Vice President and Chief Medical Officer, Wui-Jin Koh, MD, will present on NCCN's ongoing global work to define and advance high-quality, high-value, patient-centered cancer care. As part of that work, the non-profit alliance of leading cancer centers recently published the new NCCN Framework for Resource Stratification of NCCN Guidelines (NCCN Framework™) for Thyroid Carcinoma, available free-of-charge at NCCN.org/global. The new resource will debut in front of more than 1,000 cancer care providers from across the globe on June 17, 2023.

Key Points: 
  • NCCN Framework for Resource Stratification of the NCCN Guidelines (NCCN Framework™) for Thyroid Carcinoma to be presented at upcoming World Congress on Thyroid Cancer in London, UK.
  • PLYMOUTH MEETING, Pa. and LONDON, June 14, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) is introducing a new global resource to improve thyroid cancer care in low- and middle-income countries at the upcoming World Congress on Thyroid Cancer, in London.
  • NCCN Framework™ exists for numerous cancer types—covering more than 80 percent of cancer diagnoses—plus supportive care topics such as pain management, palliative care, and breast cancer prevention and detection.
  • The NCCN Framework™ for Thyroid Carcinoma is the first new cancer type to be added to this library in recent years.

Global Doxorubicin Market Report 2023: Growing Demand for Effective Cancer Treatments Fuels the Sector - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 8, 2023
Pharmaceutical, Health, Oncology, Doxorubicin, DNA, Streptomyces, Cell death, Hair loss, Multiple myeloma, Bone marrow suppression, Cancer, Lung cancer, Bladder cancer, Immunotherapy, Cardiotoxicity, USD, Vomiting, DNA replication, Stomach cancer, Incidence, Anthracycline, Patient, Risk, B-cell lymphoma, Hodgkin lymphoma, Nausea, Growth, Ovarian cancer, Thyroid cancer, Breast cancer, Mouth ulcer, Extrusion, Pharmaceutical industry

The "Global Doxorubicin Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Doxorubicin Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.
  • The global doxorubicin market size attained a value of USD 1218 million in 2022.
  • [Doxorubicin is used primarily in the treatment of a wide range of cancers, including breast cancer, ovarian cancer, lung cancer, stomach cancer, thyroid cancer, bladder cancer, multiple myeloma, Hodgkin's lymphoma, and non-Hodgkin's lymphomas.
  • The global market for doxorubicin is expected to continue to grow in the coming years, driven by an increasing incidence of cancer and a growing demand for effective treatments.

Immodulon Appoints Experienced Clinical and Medical Affairs Executive Josefine Roemmler-Zehrer, MD, Associate Professor, as Chief Medical Officer

Retrieved on: 
Monday, June 5, 2023
Pancreatic cancer, Amgen, Medicine, Drug development, University, Associate professor, Ipsen, NSCLC, Associate, MD, Patient, Internal medicine, Josefine, Ludwig Maximilian University of Munich, Diabetes, Neurology, Mortality, Thyroid cancer, Rare disease, Rare, Renal cell carcinoma, Pharmaceutical industry, Inflammation, Dermatology, Rheumatology, Endocrinology

Josefine Roemmler-Zehrer, former Medical Director at Ipsen & Celgene, brings broad global clinical and medical affairs expertise

Key Points: 
  • Josefine Roemmler-Zehrer, former Medical Director at Ipsen & Celgene, brings broad global clinical and medical affairs expertise
    Uxbridge, UK – 5 June 2023 – Immodulon, a late-stage clinical company developing a highly differentiated cancer immunotherapy that primes the patient’s own innate immune system, today announces it has appointed Dr Josefine Roemmler-Zehrer, Associate Professor as Chief Medical Officer.
  • She brings a significant track record of clinical and medical affairs success to Immodulon at a key time as the company prepares to advance IMM-101 into a pivotal trial in pancreatic cancer.
  • “I am delighted to welcome incoming Josefine to the new leadership team at Immodulon as we prepare to advance our lead asset IMM-101 into a pivotal trial, said Gertjan Bartlema, Chief Executive Officer of Immodulon.
  • “Josefine brings a wealth of global experience in clinical and medical affairs from leading pharmaceutical companies and will be instrumental in our efforts to unlock the full potential of IMM-101.

Latest Vitrakvi® (larotrectinib) Subgroup Analyses at ASCO 2023 Showcase Long-Term Efficacy and Safety Profile in Adult and Pediatric Patients with NTRK Gene Fusion Cancer, Across Solid Tumors

Retrieved on: 
Friday, June 2, 2023
General Health, Pharmaceutical, Health, Oncology, Hypersensitivity, DTC, IRC, Central nervous system, NGS, Trae tha Truth, Lung cancer, Mutation, NTRK1, CNS, ASCO, Bayer, Food and Drug Administration Amendments Act of 2007, American Society of Clinical Oncology, Dor, Myalgia, Patient, Data, NTRK, Anemia, Annual general meeting, Disease, Anaplastic thyroid cancer, ALT, ATC, FDA, AST, Society, NTRK2, Thyroid cancer, ORR, TC, Food, Safety, TRK, Pharmaceutical industry

The data was presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting from June 2-6, 2023.

Key Points: 
  • The data was presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting from June 2-6, 2023.
  • Patients should be selected for therapy based on a Food and Drug Administration (FDA)-approved test.
  • The results encourage wider adoption of next-generation sequencing (NGS) testing for identifying patients with solid tumors harboring NTRK gene fusions, including lung cancer.
  • Vitrakvi was evaluated in updated subgroup analyses of patients (n=30; data cut-off July 20, 2022) with TRK fusion thyroid cancer (TC).

Billions is spent on cancer research globally – but is it money well spent?

Retrieved on: 
Friday, June 2, 2023
Vaccine, Gaps, US Food Sovereignty Alliance, Human, European Medicines Agency, Clinical trial, Cancer, Lung cancer, Quality of life, Hope, Cancer Research UK, Breast, Global health, Research, Medicine, COVID, Life expectancy, Lung, Leukemia, Death, Neoplasm, Patient, Diagnosis, Health, Thyroid cancer, Food, Disease, Pharmaceutical industry, Uranium mining, Medical imaging, Dietary supplement

Poorer countries will be especially hard hit, with an increasing number of cases and more deaths, compared with richer countries.

Key Points: 
  • Poorer countries will be especially hard hit, with an increasing number of cases and more deaths, compared with richer countries.
  • Cancer research is vital to helping ease this global burden, but where and how research money is spent doesn’t always match with where and how help is needed.
  • To get a clearer picture of where cancer research funding is spent, we collected and compiled data covering public and charitable cancer research investments, globally, between 2016 and 2020, inclusive.
  • By country, the US provided 57.3% of the total cancer research funding awarded, with the US National Institute of Health being by far the biggest funder.

Lung and thyroid cancers least funded

    • Our analysis compares the level of funding given to researching different types of cancers with the health burden of those types of cancer.
    • In terms of the type of research, preclinical research (typically laboratory studies) received US$18 billion (73.5%).
    • Our results suggest that lung cancer was particularly poorly funded.
    • Here, thyroid cancer came out as least-well funded.
    • Both lung and thyroid cancers were judged to be the least well-funded cancer conditions overall, compared to their global burdens.

Cancer funding fell 45%

    • This might have been a natural fluctuation – cancer funding levels were declining to some extent – but it’s possible the drop was caused by a diversion of funds into COVID research.
    • It’s also likely that these drops in funding will mean less new knowledge coming through the cancer research pipeline.
    • Our analysis showed the flow of funding into cancer research.
    • Ramsey Cutress receives grant funding from the NIHR, Prevent breast cancer, World Cancer Research Fund, Association of Breast Surgery, Astra Zeneca and institutional research support from seca.